Jounce Therapeutics to Present New Data on a Potential Predictive Biomarker from the Vopratelimab ICONIC Trial at the 2020 AS...
December 19 2019 - 3:00PM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that new
data from the vopratelimab ICONIC trial, on the association of a
predictive RNA signature with the emergence of ICOS hi CD4 T cells
and clinical outcomes, will be presented at a poster session at the
2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting,
being held February 6-8, 2020 in Orlando, Florida.
“We are pleased to present the new data that led to our
selection of a predictive biomarker for our next vopratelimab
trial. We believe patient selection strategies to identify patients
more likely to respond to immuno-oncology therapies may better
address unmet medical needs,” said Elizabeth Trehu, M.D., chief
medical officer of Jounce Therapeutics. “The potential predictive
biomarker that we will present at ASCO-SITC is an RNA signature. In
2020, we plan to initiate the new Phase 2 predictive biomarker
trial, which will study vopratelimab in combination with our
investigational PD-1 inhibitor, JTX-4014, in RNA signature selected
patients.”
|
Poster
Presentation Details |
|
|
Title: |
Association of a predictive RNA
signature (RS) with emergence of ICOS hi CD4 T cells and efficacy
outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab
(nivo) in patients (pts) on the ICONIC trial |
Author: |
Timothy A. Yap, M.B.B.S., Ph.D.,
M.R.C.P., B.S., The University of Texas MD Anderson Cancer
Center |
Session
Title: |
Poster Session A |
Abstract
Number: |
14 |
Session Date and
Time: |
Thursday, February 6, 2020, 11:30
AM-1:00 PM and 6:00 PM-7:00 PM ET |
|
|
About Vopratelimab Jounce’s lead product
candidate, vopratelimab (formerly JTX-2011), is a clinical-stage
monoclonal antibody that binds to and activates ICOS, the
Inducible T cell
CO-Stimulator, a protein on the
surface of certain T cells commonly found in many solid tumors.
Vopratelimab is currently being assessed in the Phase 2 EMERGE
clinical trial in sequence with ipilimumab in patients with
non-small cell lung cancer (NSCLC) or urothelial cancer who were
previously treated with PD-1/PD-L1 inhibitor therapies. Jounce is
also planning to initiate a new predictive biomarker trial of
vopratelimab with its investigational PD-1 inhibitor, JTX-4014, in
RNA signature selected patients. Vopratelimab was previously
assessed in the Phase 1/2 ICONIC trial and was found to be safe and
well-tolerated, alone and in combination with each of the anti-PD-1
antibodies nivolumab and pembrolizumab, as well as with ipilimumab,
an antibody that binds to CTLA-4. Jounce has previously presented
data demonstrating the emergence of ICOS hi CD4 T cells in the
peripheral blood in patients treated with vopratelimab alone or in
combination with nivolumab, and has further shown that emergence of
these cells, which is related to vopratelimab and not PD-1
inhibitors, is associated with improved response rate, progression
free survival, and overall survival.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Through
the use of its Translational Science Platform, Jounce first focuses
on specific cell types within the human tumor microenvironment to
prioritize targets, and then identifies related biomarkers designed
to match the right immunotherapy to the right patient. Jounce is
developing two clinical-stage programs, vopratelimab, a monoclonal
antibody that binds to and activates ICOS, and JTX-4014, a PD-1
inhibitor intended for potential combination use with Jounce’s
broader pipeline. Vopratelimab is currently being assessed in a
Phase 2 clinical trial and JTX-4014 Phase 1 data were reported in
November 2019 with additional studies planned. Jounce is also
advancing and building out its broad and wholly-owned discovery
pipeline of immuno-oncology targets, including those expressed on
T-regulatory cells, macrophages and stromal cells. In addition,
Jounce has exclusively licensed worldwide rights to JTX-8064, a
LILRB2 receptor antagonist, to Celgene, a wholly owned subsidiary
of Bristol-Myers Squibb Company. For more information, please visit
www.jouncetx.com.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Kathryn MorrisThe Yates
Network914-204-6412kathryn@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024